Covered recipient · General Payments record
VICTOR T G LIN
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$3,084.71
141 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,004.71 | 140 |
| Education | $80.00 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
VICTOR T G LIN
NPI 1568806818 · CMS profile ID 1388265
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
BATON ROUGE, LA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1568806818?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- VICTOR T G LIN, NPI 1568806818, CMS profile ID 1388265. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568806818?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). VICTOR T G LIN, NPI 1568806818, CMS profile ID 1388265. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568806818?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- VICTOR T G LIN, NPI 1568806818, CMS profile ID 1388265, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1568806818?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
141 matching records · $3,084.71 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–141 of 141.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Fennec Pharmaceuticals, Inc. | $24.59 | 04/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250854870 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.46 | 04/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223869688 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.39 | 04/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206633583 | CMS |
| Daiichi Sankyo Inc. | $27.50 | 04/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197060749 | CMS |
| Novartis Pharmaceuticals Corporation | $24.09 | 04/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200740863 | CMS |
| Merck Sharp & Dohme LLC | $27.56 | 03/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238144824 | CMS |
| ARRAY BIOPHARMA INC | $18.78 | 03/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231391641 | CMS |
| Ipsen Biopharmaceuticals, Inc | $20.85 | 03/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1208845631 | CMS |
| Alexion Pharmaceuticals, Inc. | $18.54 | 03/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202957838 | CMS |
| Karyopharm Therapeutics Inc. | $16.00 | 03/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246652932 | CMS |
| Novartis Pharmaceuticals Corporation | $25.53 | 03/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200740861 | CMS |
| Aveo Pharmaceuticals, Inc. | $21.15 | 03/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1199902488 | CMS |
| Alnylam Pharmaceuticals Inc. | $18.90 | 03/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212798187 | CMS |
| Janssen Biotech, Inc. | $14.88 | 03/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174569015 | CMS |
| Daiichi Sankyo Inc. | $27.50 | 03/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197098121 | CMS |
| Rigel Pharmaceuticals, Inc. | $14.70 | 03/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247370708 | CMS |
| Cumberland Pharmaceuticals, Inc. | $13.65 | 03/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242140038 | CMS |
| Adaptive Biotechnologies Corporation | $23.43 | 03/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1254940782 | CMS |
| Janssen Biotech, Inc. | $24.01 | 02/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174571710 | CMS |
| ABBVIE INC. | $18.54 | 02/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202308263 | CMS |
| Genentech USA, Inc. | $18.55 | 02/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211604583 | CMS |
| Celgene Corporation | $20.92 | 02/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184673901 | CMS |
| Celgene Corporation | $17.73 | 02/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184673905 | CMS |
| Tempus AI, Inc | $17.95 | 02/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250348262 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.92 | 02/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206170463 | CMS |
| BeiGene USA, Inc. | $18.18 | 02/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202878664 | CMS |
| GENZYME CORPORATION | $20.68 | 02/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233209178 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $21.71 | 02/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225626760 | CMS |
| Exelixis Inc. | $21.31 | 02/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218807145 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.79 | 01/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206259488 | CMS |
| Spectrum Pharmaceuticals Inc. | $19.33 | 01/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1221050500 | CMS |
| ABBVIE INC. | $23.55 | 01/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202308261 | CMS |
| Novartis Pharmaceuticals Corporation | $20.71 | 01/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200740859 | CMS |
| SpringWorks Therapeutics, Inc. | $17.03 | 01/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232164501 | CMS |
| Merck Sharp & Dohme LLC | $19.03 | 01/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238059517 | CMS |
| Janssen Biotech, Inc. | $13.88 | 01/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174562231 | CMS |
| PFIZER INC. | $18.98 | 01/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1230065176 | CMS |
| PharmaEssentia USA Corporation | $25.33 | 01/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246826452 | CMS |
| Incyte Corporation | $26.70 | 01/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225991111 | CMS |
| Janssen Biotech, Inc. | $17.91 | 01/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174572397 | CMS |
| Daiichi Sankyo Inc. | $28.76 | 01/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197077299 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $6,101.34 | 2 |
| PY2025 | Principal investigator | $795,142.05 | 63 |
| PY2024 | Principal investigator | $804,779.45 | 52 |
| PY2023 | Principal investigator | $644,023.40 | 44 |
| PY2022 | Principal investigator | $42,912.20 | 7 |
| PY2021 | Principal investigator | $6,530.00 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
65 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Eli Lilly and Company | $56,045.00 | 12/31/2025 | Non-covered Recipient Entity THE ON EONCOLOGY RESEARCH NETWORK LLC | AN OPEN-LABEL, MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS | No dispute reported | 06/30/2026 | 1187893570 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $15,450.74 | 12/31/2025 | Non-covered Recipient Entity Mary Bird Perkins Cancer Center Baton Rouge | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with r | No dispute reported | 06/30/2026 | 1232917483 |
| Principal investigator 1 | Genentech, Inc. | $42,812.25 | 12/15/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC ONEONCOLOGY PARENT HLDG LLC | INTRINSIC mCRC with specific genomic alterations | No dispute reported | 06/30/2026 | 1211635190 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $279.06 | 11/10/2025 | Non-covered Recipient Entity Mary Bird Perkins Cancer Center | Head And Neck Cancer Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1199910925 |
| Principal investigator 1 | Genentech, Inc. | $195.00 | 11/10/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC ONEONCOLOGY PARENT HLDG LLC | INTRINSIC mCRC with specific genomic alterations | No dispute reported | 06/30/2026 | 1211635185 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,000.00 | 11/07/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184257859 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 10/23/2025 | Non-covered Recipient Entity ONEONCOLOGY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192097714 |
| Principal investigator 1 | Genentech, Inc. | $13,115.00 | 10/17/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC ONEONCOLOGY PARENT HLDG LLC | INTRINSIC mCRC with specific genomic alterations | No dispute reported | 06/30/2026 | 1211635180 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $88.99 | 09/30/2025 | Non-covered Recipient Entity Mary Bird Perkins Cancer Center | A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-4) | No dispute reported | 06/30/2026 | 1235996103 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 09/17/2025 | Non-covered Recipient Entity ONEONCOLOGY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192097743 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,000.00 | 09/12/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184236686 |
| Principal investigator 1 | Celgene Corporation | $67,206.35 | 09/03/2025 | Non-covered Recipient Entity Oneoncology | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | No dispute reported | 06/30/2026 | 1222306999 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 08/28/2025 | Non-covered Recipient Entity ONEONCOLOGY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192189540 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 08/26/2025 | Non-covered Recipient Entity ONEONCOLOGY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192189544 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $22,090.28 | 08/22/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK LLC | A Master Protocol of an Open-Label Multi-Drug Multi-Centre Phase II Study to Evaluate the Efficacy Safety Tolerability Pharmacokinetics and Immunogenicity of Novel Combinations in Participants with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | No dispute reported | 06/30/2026 | 1185537449 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $13,104.63 | 08/22/2025 | Non-covered Recipient Entity MARY BIRD PERKINS CANCER CENTER | An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus Observation to delay castration or disease recurrence in adult male patients with PSMA positive Oligometastatic Prostate Cancer (OMPC) | No dispute reported | 06/30/2026 | 1190311713 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $1,740.00 | 08/18/2025 | Non-covered Recipient Entity Mary Bird Perkins Cancer Center Baton Rouge | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with r | No dispute reported | 06/30/2026 | 1232917481 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $6,503.76 | 08/04/2025 | Non-covered Recipient Entity Mary Bird Perkins Cancer Center | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199910917 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $85.00 | 07/28/2025 | Non-covered Recipient Entity MARY BIRD PERKINS CANCER CENTER | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184220592 |
| Principal investigator 1 | Eli Lilly and Company | $9,877.00 | 07/15/2025 | Non-covered Recipient Entity THE ON EONCOLOGY RESEARCH NETWORK LLC | A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 | No dispute reported | 06/30/2026 | 1187892172 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $7,271.98 | 07/07/2025 | Non-covered Recipient Entity Mary Bird Perkins Cancer Center | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199910915 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 06/30/2025 | Non-covered Recipient Entity ONEONCOLOGY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192097728 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,750.00 | 06/27/2025 | Non-covered Recipient Entity ONEONCOLOGY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192097735 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $279.06 | 06/18/2025 | Non-covered Recipient Entity Mary Bird Perkins Cancer Center | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199910923 |
| Principal investigator 1 | Eli Lilly and Company | $5,999.00 | 06/17/2025 | Non-covered Recipient Entity THE ON EONCOLOGY RESEARCH NETWORK LLC | SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION | No dispute reported | 06/30/2026 | 1187891220 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $10,000.00 | 06/03/2025 | Non-covered Recipient Entity MARY BIRD PERKINS CANCER CENTER | An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus Observation to delay castration or disease recurrence in adult male patients with PSMA positive Oligometastatic Prostate Cancer (OMPC) | No dispute reported | 06/30/2026 | 1190305361 |
| Principal investigator 1 | Genentech, Inc. | $21,108.00 | 05/28/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC ONEONCOLOGY PARENT HLDG LLC | INTRINSIC mCRC with specific genomic alterations | No dispute reported | 06/30/2026 | 1211635166 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 05/13/2025 | Non-covered Recipient Entity ONEONCOLOGY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192097767 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 05/13/2025 | Non-covered Recipient Entity ONEONCOLOGY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192150623 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $906.75 | 05/12/2025 | Non-covered Recipient Entity Mary Bird Perkins Cancer Center | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199910921 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 05/12/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK LL C | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | No dispute reported | 06/30/2026 | 1175421238 |
| Recipient | F. Hoffmann-La Roche AG | $3,050.67 | 05/08/2025 | Covered Recipient Physician | A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment | No dispute reported | 06/30/2026 | 1211539469 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $14,000.00 | 05/02/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184191969 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,000.00 | 05/02/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184191971 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 05/02/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184191973 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $114,607.31 | 04/30/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK LLC | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | No dispute reported | 06/30/2026 | 1185537453 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,541.00 | 04/28/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK LL C | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | No dispute reported | 06/30/2026 | 1175421182 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,500.00 | 04/28/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK LL C | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | No dispute reported | 06/30/2026 | 1175421189 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,227.90 | 04/28/2025 | Non-covered Recipient Entity MARY BIRD PERKINS CANCER CENTER | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184190357 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,463.35 | 04/28/2025 | Non-covered Recipient Entity MARY BIRD PERKINS CANCER CENTER | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184190359 |
| Principal investigator 1 | Eli Lilly and Company | $866.01 | 04/23/2025 | Non-covered Recipient Entity MARY BIRD PERKINS CANCER CENTER | A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 | No dispute reported | 06/30/2026 | 1187886160 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $5,907.33 | 04/11/2025 | Non-covered Recipient Entity Mary Bird Perkins Cancer Center | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199910919 |
| Principal investigator 1 | Eli Lilly and Company | $95,861.60 | 04/03/2025 | Non-covered Recipient Entity MARY BIRD PERKINS CANCER CENTER | A PHASE 1A/1B STUDY OF LY3537982 IN PATIENTS WITH KRAS G12C-MUTANT ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1187886792 |
| Recipient | F. Hoffmann-La Roche AG | $3,050.67 | 03/31/2025 | Covered Recipient Physician | A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment | No dispute reported | 06/30/2026 | 1211539473 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 03/21/2025 | Non-covered Recipient Entity ONEONCOLOGY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192097721 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 03/21/2025 | Non-covered Recipient Entity ONEONCOLOGY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192150627 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $8,128.29 | 03/18/2025 | Non-covered Recipient Entity Mary Bird Perkins Cancer Center | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199910913 |
| Principal investigator 1 | BeiGene USA, Inc. | $1,573.00 | 03/04/2025 | Non-covered Recipient Entity Mary Bird Perkins Cancer Center | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190320236 |
| Principal investigator 1 | BeiGene USA, Inc. | $1,413.00 | 02/25/2025 | Non-covered Recipient Entity Mary Bird Perkins Cancer Center | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190320234 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 02/24/2025 | Non-covered Recipient Entity ONEONCOLOGY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192150618 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $22,750.00 | 02/12/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK LLC | A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy | No dispute reported | 06/30/2026 | 1185537451 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 02/10/2025 | Non-covered Recipient Entity ONEONCOLOGY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192097750 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 02/10/2025 | Non-covered Recipient Entity ONEONCOLOGY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192097756 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,750.00 | 02/07/2025 | Non-covered Recipient Entity ONEONCOLOGY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192097762 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 02/07/2025 | Non-covered Recipient Entity ONEONCOLOGY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192150631 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $9,588.15 | 02/03/2025 | Non-covered Recipient Entity Mary Bird Perkins Cancer Center | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199910905 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $41,077.16 | 02/03/2025 | Non-covered Recipient Entity Mary Bird Perkins Cancer Center | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199910909 |
| Principal investigator 1 | Celgene Corporation | $65,818.60 | 01/29/2025 | Non-covered Recipient Entity Oneoncology | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | No dispute reported | 06/30/2026 | 1222306957 |
| Principal investigator 1 | Eli Lilly and Company | $2,351.73 | 01/27/2025 | Non-covered Recipient Entity MARY BIRD PERKINS CANCER CENTER | SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION | No dispute reported | 06/30/2026 | 1187885464 |
| Principal investigator 1 | BeiGene USA, Inc. | $22,698.00 | 01/21/2025 | Non-covered Recipient Entity Mary Bird Perkins Cancer Center | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190322580 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $11,911.77 | 01/07/2025 | Non-covered Recipient Entity Mary Bird Perkins Cancer Center | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199910907 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $450.00 | 01/07/2025 | Non-covered Recipient Entity Mary Bird Perkins Cancer Center | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199910911 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 01/07/2025 | Non-covered Recipient Entity ONEONCOLOGY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192150610 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 01/07/2025 | Non-covered Recipient Entity ONEONCOLOGY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192150614 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 01/07/2025 | Non-covered Recipient Entity ONEONCOLOGY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192150635 |